Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, "Klotho" mouse

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue 6, 2002, Pages 545-553

  Takeshita, Kyosuke ^a   Yamamoto, Koji ^a   Ito, Masafumi ^b   Kondo, Takahisa ^a   Matsushita, Tadashi ^a   Hirai, Makoto ^a   Kojima, Tetsuhito ^c   Nishimura, Masahiko ^a   Nabeshima, Yoichi ^d   Loskutoff, David J ^e   Saito, Hidehiko ^f   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Fibrinolysis; Gene expression; Proteolysis; Sclerosis; Thrombosis

Indexed keywords

ANTIGEN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADRENAL MEDULLA; AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIFICATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBRIN DEPOSITION; FIBRINOLYSIS; GENE EXPRESSION; GLOMERULUS; HEART MUSCLE CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY TUBULE EPITHELIUM; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SMOOTH MUSCLE; THROMBOSIS;

AGING; ANIMALS; FIBRIN; GENE EXPRESSION; GLUCURONIDASE; KIDNEY; MEMBRANE PROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MODELS, ANIMAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; THROMBOSIS; TISSUE DISTRIBUTION;

EID: 12244263052     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-36699     Document Type: Article

References (30)

1. Tracy RP, Bovill EG. Thrombosis and cardiovascular risk in the elderly. Arch Pathol Lab Med 1992;116:1307-1312
2. Sagripanti A, Carpi A. Natural anticoagulants, aging, and thromboembolism. Exp Gerontol 1998;33:891-896
3. Kiechl S, Willeit J. The natural course of atherosclerosis. Part II: Vascular remodeling. Arterioscler Thromb Vasc Biol 1999; 19:1491-1498
4. Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population. I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985;54:475-479
5. Kurachi S, Deyashiki Y, Takeshita J, Kurachi K. Genetic mechanisms of age regulation of human blood coagulation factor IX. Science 1999;285:739-743
6. Köster T, Rosendaal FR, Reitsma PH, van der Velden PA, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - The Leiden Thrombophilia Study (LETS). Thromb Haemost 1994;71:719-722
7. Woodward M, Lowe GDO, Rumley A, et al. Epidemiology of coagulation factors, inhibitors and activation markers: The third Glasgow MONICA survey II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1997;97:785-797
8. Aillaud MF, Pignol F, Alessi MC, et al. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age. Thromb Haemost 1986;55:330-332
9. Hashimoto Y, Kobayashi A, Yamazaki N, et al. Relationship between age and plasma t-PA, PA-inhibitor, and PA activity. Thromb Res 1987;46:625-633
10. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Progr Hemost Thromb 1988;10:87-115
11. Yamamoto K, Saito H. A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int J Hematol 1998;68:371-385
12. Kohler HP, Grant PJ. Plasminogen activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-1801
13. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-1563
14. Hamsten A, de Faire U, Walldius G. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9
15. Jørgensen M, Bonnevie-Nielsen V. Increased concentration of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis. Br J Haematol 1987;65:175-180
16. Pralong G, Calandra T, Glauser M-P, et al. Plasminogen activator inhibitor 1: A new prognostic marker in septic shock. Thromb Haemost 1989;61:459-462
17. Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89:6998-7002
18. Lupu F, Bergonzelli GE, Heim DA, et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993;13:1090-1100
19. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000;96:4212-4215
20. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51
21. Shiraki-Iida T, Aizawa H, Matsumura Y, et al. Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein. FEBS Lett 1998;424:6-10
22. Saito Y, Yamagishi T, Nakamura T, et al. Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 1998;248:324-329
23. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987;79:124-130
24. Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 1996;97:2440-2451
25. Schleef RR, Sinha M, Loskutoff DJ. Immunoradiometric assay to measure the binding of a specific inhibitor to tissue-type plasminogen activator. J Lab Clin Med 1985;106:408-415
26. Gibson UEM, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1001
27. Yamamoto K, Loskutoff DJ. The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis. Am J Pathol 1997;151:725-734
28. Abrass CK, Adcox MJ, Raugi GJ. Aging-associated changes in renal extracellular matrix. Am J Pathol 1995;146:742-752
29. Moll S, Schifferli JA, Huarte J, et al. LPS induces major changes in the extracellular proteolytic balance in the murine kidney. Kidney Int 1994;45:500-508
30. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J Clin Invest 1991;88:1346-1353